Brought to you by 
CancerVax, YM Bio and CIMAB in cancer deal
25 Feb 2021
Executive Summary
Cancer therapeutics company CancerVax's Tarcanta and Tarcanta Ltd. subsidiaries have licensed from CIMAB SA (commercial branch of Cuba's Center of Molecular Immunology and YM BioSciences (cancer; has an existing relationship with YM) exclusive rights to complete clinical development on three oncology immunotherapeutics. CancerVax also gets rights to commercialize successful products from the deal in the US, Western Europe, Canada, Japan, Australia, New Zealand, and Mexico.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CancerVax, YM Bio and CIMAB in cancer deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice